<?xml version="1.0" encoding="UTF-8"?>
<p id="Par37">In November and December 2013, the US Food and Drug Administration approved the use of two new drugs for the treatment of chronic HCV infection, simeprevir and sofosbuvir. These drugs are approved for use in HCV-infected patients with genotypes 1 and 4, which showed &gt;90 % SVR rates in clinical trials [
 <xref ref-type="bibr" rid="CR60">60</xref>]. Although treatment is very costly, these are among the new drugs that offer promising hope towards the global eradication of hepatitis C. As new therapies continue to be developed, evidence-based hepatitis C management recommendations are continuously updated to address issues ranging from testing and linkage to care to the optimal treatment regimen in specific patient situations [
 <xref ref-type="bibr" rid="CR36">36</xref>].
</p>
